Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31368123 | 0.88 | CNR2 (0.49) | CNR2CNR1HTTGAAMAPT | |
| SCHEMBL31368076 | 0.84 | CNR2 (0.48) | CNR2CNR1HTTFEN1KDM4E | |
| SCHEMBL31368125 | 0.84 | CNR2 (0.48) | CNR2CNR1HTTFEN1KDM4E | |
| SCHEMBL31368046 | 0.84 | CNR2 (0.47) | CNR2CNR1HTTFEN1KDM4E | |
| SCHEMBL18698713 | 0.83 | CNR2 (0.50) | CNR2CNR1FEN1 | |
| SCHEMBL18698726 | 0.80 | CNR2 (0.47) | CNR2CNR1HTTFEN1GAA | |
| SCHEMBL31368129 | 0.78 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL31368153 | 0.77 | CNR2 (0.47) | CNR2CNR1HTTTP53MAPT | |
| SCHEMBL31368095 | 0.77 | CNR2 (0.47) | CNR2CNR1HTTTP53MAPT | |
| SCHEMBL17956272 | 0.77 | CNR2 (0.53) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025037229-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | MAPK1, MAP3K1, MAPK6 | CNR2 2020/4885CNR1 1719/4885HTT 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.